Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Celeste Lorusso"'
Publikováno v:
Cells, Vol 9, Iss 2, p 415 (2020)
The number of treatment options for melanoma patients has grown in the past few years, leading to considerable improvements in both overall and progression-free survival. Targeted therapies and immune checkpoint inhibitors have opened a new era in th
Externí odkaz:
https://doaj.org/article/aa010767708d439f87528b7fe67b637e
Autor:
Alessandra Mangia, Giovanni Cenderello, Massimiliano Copetti, Gabriella Verucchi, Valeria Piazzolla, Celeste Lorusso, Rosanna Santoro, Maria Maddalena Squillante, Alessandra Orlandini, Rosalba Minisini, Alessia Ciancio
Publikováno v:
Cells, Vol 8, Iss 4, p 313 (2019)
In clinical trials, a sofosbuvir/velpatasvir (SOF/VEL) pangenotypic single-tablet regimen was associated with high sustained virological response (SVR) rates at 12 weeks (SVR12) after the end of treatment, regardless of genotype and fibrosis stage. N
Externí odkaz:
https://doaj.org/article/28005e984362490485c528fccc3409f7
Autor:
Alessia Ciancio, Rosanna Santoro, Alessandra Mangia, Alessandra Orlandini, Valeria Piazzolla, Rosalba Minisini, Maria Maddalena Squillante, Massimiliano Copetti, Gabriella Verucchi, Giovanni Cenderello, Celeste Lorusso
Publikováno v:
Cells
Cells, Vol 8, Iss 4, p 313 (2019)
Volume 8
Issue 4
Cells, Vol 8, Iss 4, p 313 (2019)
Volume 8
Issue 4
In clinical trials, a sofosbuvir/velpatasvir (SOF/VEL) pangenotypic single-tablet regimen was associated with high sustained virological response (SVR) rates at 12 weeks (SVR12) after the end of treatment, regardless of genotype and fibrosis stage. N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::036051e911b3d405306f593d887b1a7f
http://hdl.handle.net/11585/727531
http://hdl.handle.net/11585/727531
Publikováno v:
Cells, Vol 9, Iss 2, p 415 (2020)
Cells
Cells
The number of treatment options for melanoma patients has grown in the past few years, leading to considerable improvements in both overall and progression-free survival. Targeted therapies and immune checkpoint inhibitors have opened a new era in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bd81f87838f2bfb6dea1d80d2d13ae3
https://doi.org/10.3390/cells9020415
https://doi.org/10.3390/cells9020415